Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer

British Journal of Cancer

Volumn 107, Issue 2, 2012, Pages 382-387

  Morrison, D H ^a   Rahardja, D ^b   King, E ^a   Peng, Y ^a   Sarode, V R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

breast biomarkers; molecular subtypes; young age

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR MARKER;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; FEMALE; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INDEX FINGER; INVASIVE BREAST CANCER; LABELING INDEX; LUMINAL B BREAST CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PLOIDY; PRIORITY JOURNAL; RACE DIFFERENCE; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGE FACTORS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863728650     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.219     Document Type: Article

References (34)

1. Aebi S, Gelber S, Castogione-Gertsch M, Gelber RD, Collins J, Thürlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A (2000) Is chemotherapy alone adequate for young women with oestrogen receptor positive breast cancer? Lancet 355: 1869-1874
2. Agrup M, Stal O, Olsen K, Wingren S (2002) C-erb-2 over-expression and survival in early onset breast cancer. Breast Can Res Treat 63: 23-29
3. Ahn SJ, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, Han W, Korean Breast Cancer Society (2007) Poor outcome of hormone receptor-positive breast cancer at very young age Is due to tamoxifen resistance: nationwide survival data in Korea-a report from the Korean Breast Cancer Society. J Clin Oncol 25: 2360-2368
4. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26: 3324-3330
5. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A (2009) Breast cancer before age 40 years. Semin Oncol 36: 237-249
6. Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G, Dabbs DJ (2009) Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol 2: 444-455
7. Bolton KL, Garcia-Closas M, Pfeiffer RM, Duggan MA, Howat WJ, Hewitt SM, Yang XR, Cornelison R, Anzick SL, Meltzer P, Davis S, Lenz P, Figueroa JD, Pharoah PD, Sherman ME (2010) Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies. Cancer Epidemiol Biomarkers Prev 19: 992-999
8. Bonnier P, Romain S, Charpin C, Lejeune C, Tubiana N, Martin PM, Piana L (1995) Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer 17: 138-144
9. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Veronesi P, Torrisi R, Montagna E, Luini A, Intra M, Gentilini O, Ghisini R, Goldhirsch A, Colleoni M (2010) Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (o35 years) with operable breast cancer. Ann Oncol 21: 1974-1981
10. Carey L, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502
11. Chae BJ, Bae JS, Lee A, Park WC, Seo YJ, Song BJ, Kim JS, Jung SS (2009) p53 as a specific prognostic factor in triple negative breast cancer. Jpn J Clin Oncol 39: 217-224
12. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, Her2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101: 736-750
13. Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, Luini A, Veronesi P, Intra M, Orecchia R, Catalano G, Galimberti V, Nolé F, Martinelli G, Goldhirsch A (2002) Very young women (o35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13: 273-279
14. Crabb SJ, Cheang MC, Leung S, Immonen T, Nielsen TO, Huntsman DD, Bajdik CD, Chia SK (2008) Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastasis in primary breast cancer. Clin Breast Cancer 8: 249-256
15. Faratian D, Kay C, Robson T, Campbell FM, Grant M, Rea D, Bartlett JM (2009) Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large scale clinical studies: the TEAM trial experience. Histopathology 55: 587-593
16. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363: 1938-1948
17. Fulford LG, Reiss-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A, Easton D, Lakhani SR (2007) Basal like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 9: R4
18. Gokhale S, Rosen D, Sneige N, Diaz LK, Resetkova E, Sahin A, Liu J, Albarracin CT (2007) Assessment of two automated imaging systems in evaluation of estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol 154: 451-455
19. Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD (2001) TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ line mutations: distinctive spectrum and structural distribution. Can Res 61: 4092-4097
20. Haffty BG, Buchholz TA (2010) Molecular predictors of locoregional recurrence in breast cancer: ready for prime time? J Clin Oncol 28(10): 1627-1629
21. Hartley M, McKinley B, Rogers EA, Kalbaugh CA, Messich HS, Blackhurst DW, Lokey JS, Trocha SD (2006) Differential expression of prognostic factors and effect on survival in young (o or 40) breast cancer patients. A case control study. Am Surg 72: 1189-1194
22. Ihemelandu CU, Leffall Jr LD, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA (2007) Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res 143: 109-118
23. Lin CH, Liau JY, Lu YS, Huang CS, Lee WC, Kuo KT, Shen YC, Kuo SH, Lan C, Liu JM, Kuo WH, Chang KJ, Cheng AL (2009) Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev 18: 1807-1814
24. Maru D, Middleton LP, Wang S, Valero V, Sahin A (2005) Her2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger. Cancer 103: 900-905
25. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen treated node negative breast cancer. N Engl J Med 351(27): 2817-2826
26. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, Lashkari D, Shalon D, Brown PO, Botstein D (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96: 9212-9217
27. Rakha EA, Elshiekh SE, Aleskandaray MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO (2009) Triple negative breast cancer. Distinguishing between basal and nonbasal subtypes. Clin Can Res 15: 2302-2310
28. Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML, Norton L, Offit K (1998) BRCAassociated breast cancer in young women. J Clin Oncol 16: 1642-1649
29. Shavers VL, Harlan LC, Stevens JL (2003) Racial/ethnic variation in clinical presentation, treatment and survival among breast cancer patients under age 35. Cancer 1: 134-147
30. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Pro Natl Acad Sci USA 98: 10869-10874
31. Sotriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Pro Natl Acad Sci USA 100: 10393-10398
32. Voduc KD, Cheang MCU, Tydesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28: 1684-1691
33. Walker RA, Lees E, Webb MB, Dearing SJ (1996) Breast carcinomas occurring in young women (o35 years) are different. Br J Cancer 74: 1796-1800
34. Yerushalmi R, Woods R, Ravdin P, Hayes MM, Gelmon KA (2010) Ki 67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174-183